Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

07/23/2012 | 05:04am US/Eastern
Recommend:
0

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago VECTREN : receives route approval for transmission pipeline relocation project at Dayton airport
<1m ago CLAUDE RESOURCES : Provides 2013 UG Drilling Results from the Seabee Gold Operation more...
<1m ago FEDERAL NATIONAL MORTGAGE ASSCTN FNNI ME : News Release - Fannie Mae Multifamily Provides Consistent ...
<1m ago ARROW FINANCIAL : Reports Increased Quarterly Earnings and Strong Asset Quality Ratios
<1m ago North American Palladium to Host First Quarter 2014 Results Conference Call & Webcast on May 1, and Annual & Special Meeting of Shareholders on June 23
<1m ago GROWLIFE INVESTOR ALERT : Tripp Levy PLLC Announces the Filing of a Securities Fraud Class Action Lawsuit Against GrowLife, Inc. -- PHOT
<1m ago IIROC Trade Resumption - Silver Predator Corp.
1m ago EDGE LEGAL MARKETING : Recognized in 2014 Best of The National Law Journal Readers Rankings
1m ago Good Earth Coffeehouse Grand Opening - Centennial Place, Calgary
1m ago SBLI Hosts Live Twitter Chat with Top Social-Media Influencers
Latest news
Advertisement
Hot News 
HAVELOCK EUROPA : Preliminary Results to 31 December 2013
LDK SOLAR : Provides Additional Information on its Request for Review of NYSE Regulation's Decision to Suspend Trading and Commence Delisting Procedures
HAYNES PUBLISHING : Third Quarter Hit By Us Inventory Returns, Weak UK
SPACEANDPEOPLE : Shares Slide As It Lowers 2014 Forecast
MONEYGRAM : to Host Analyst Call
Most Read News
9h ago Liverpool surge clear with a Sterling performance ; FOOTBALL
1d ago FORD MOTOR : 2001 Ford Expedition Used Engines for Sale Discounted by National Parts Retailer
9h ago Get ready for finest title win in history of the Prem ; LAWRO
1d ago GALLANT VENTURE : Annual General Meeting
10h ago DELL : U.S. insider trading cases face test at appeals court
Most recommended articles
9h ago GLOBAL MARKETS-Asian stocks subdued on Ukraine caution, dollar firms vs yen
4d ago Financials bolster FTSE after reassuring U.S. earnings
4d ago BLACKSTONE : earnings rise 30 percent, boosted by private equity gains
2m ago Canadian gold mining's bidding war shows appeal of buy over build
3m ago TSX flat in thin holiday volume; energy offsets golds
Dynamic quotes  
ON
| OFF